MDxHealth Reports First Half Year 2014 Results IRVINE,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MDxHealth Reports First Half Year 2014 Results

IRVINE, Calif. and HERSTAL, Belgium, Aug. 21, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.

"During the first half of 2014, adoption of ConfirmMDx ® for Prostate Cancer continued to grow rapidly, with 5,500 patient cases tested, compared to approximately 2,400 cases in the first half of 2013. ConfirmMDx revenue increased sharply to $3.9 million in H1 2014, rising from $0.9 million in the first half 2013. The fast growth of revenue was due to a combination of factors including test volume growth and increased recognition of revenue based on broader non-Medicare insurance coverage and improving payment and collection trends," reported Dr. Jan Groen, CEO of MDxHealth. "We also achieved a significant milestone in the Medicare coverage process during this reporting period. The Local Coverage Determination (LCD) for ConfirmMDx has been posted for public comment, signaling that the test has passed the technical assessment. Following the notification period, we anticipate that the LCD should be effective before the end of 2014."

Business Highlights

ConfirmMDx for Prostate Cancer

  • Revenue increased 317% to $3.9 million in H1 2014 over $0.9 million in H1 2013
  • Case volume increased 129%, with 5,500 patients tested in H1 2014 compared to 2,400 patients tested in H1 2013
  • Published clinical utility study in the journal American Health and Drug Benefits
  • DOCUMENT validation study published in the Journal of Urology
  • Presented data regarding the prognostic value of the ConfirmMDx test genes at the 2014 ASCO Genitourinary (GU) Seminar
  • Signed co-marketing agreements with Long Island Pathology and American Pathology Partners
  • Signed an exclusive agreement with Teva Pharmaceutical Ltd. for distribution of ConfirmMDx for Prostate Cancer in Israel
  • Signed insurance agreements with additional PPO providers Prime Health Services and Galaxy Health Network, adding nearly 10 million covered lives
  • The Centers for Medicare and Medicaid Services (CMS) posted the draft Local Coverage Determination (LCD) for the ConfirmMDx for Prostate Cancer test on its website

Other Business Activities

  • MDxHealth and HistoGeneX N.V. were awarded $1.8 million from the Flemish Institute for the Promotion of Innovation by Science and Technology to fund the development of companion diagnostics for cancer immunotherapy
  • MDxHealth licensee Exact Sciences published the positive results of its 10,000 patient DeeP-C pivotal clinical study for its Cologuard test in the New England Journal of Medicine
  • Data confirming the clinical utility of PredictMDx ® for Glioblastoma test published in the New England Journal of Medicine
  • MDxHealth received approval from the Belgium tax authority for patent income deductions (PID), which allows for an 80% deduction of qualifying gross patent income. PID treatment is granted to Belgian companies who support investments in technical innovation which stimulate ownership of patents and promotes business based on these patents. PID reduces the effective tax rate from 34% to 6.8% for the qualifying income.

Events After the Reporting Period

  • Validation Study demonstrating the prognostic value of ConfirmMDx biomarker published in The Journal of Urology ®
  • CMS initiated National Coverage Analysis for screening for colorectal cancer using Exact Sciences Cologuard test, and posted the related Proposed Decision Memorandum on its website.
  • MDxHealth licensee Exact Sciences received FDA approval for its Cologuard colon cancer screening assay
  • Signed two insurance agreements with Ancillary Care Services (ACS), and separately, with Consilium, LLC.
  • Signed a co-marketing agreement with Miraca Life Sciences, the largest independent anatomic pathology lab in the U.S., to promote ConfirmMDx.

Financials

Key Figures for the first half (thousands of U.S. dollars, except number of shares and per share data):

As of June 30, 2014 First half year 2014 First half year 2013
Total revenues 4,804 3,984
Total operating expenses 10,434 10,022
EBITDA (Loss) -7,932 -7,525
Operating profit (EBIT) -8,086 -7,820
Net loss -8,043 -7,843
Earnings per share, basic ($) -0.23 -0.23
Number of outstanding shares 34,251,303    34,251,303  
Cash and cash equivalents 12,709 32,253  

Revenues

Total revenues grew 21% to $4.8 million in H1 2014, compared to $4.0 million in H1 2013.  Revenue from ConfirmMDx sales increased 317%, with $3.9 million in H1 2014 compared to $0.9 million in H1 2013. ConfirmMDx represents 81% of the overall revenue mix in H1 2014, as compared to 23% in the same period last year.  In H1 2013 50% of MDxHealth's revenue was related to the Merck Cilengitide companion diagnostic project. The Merck agreement was terminated after Merck's Phase III clinical study did not meet its primary endpoints.

Operating Expenses

Operating expenses for H1 2014 were $10.4 million, increasing 4% compared to $10.0 million in H1 2013. This increase was attributable to the continued build-up of the U.S. commercial operations in support of ConfirmMDx for Prostate Cancer test.

Results
As expected, H1 2014 loss increased slightly over the same period in 2013 due to costs associated with growing commercial infrastructure to support U.S. sales and marketing and new product R&D investment. The company's operating loss (EBIT) increased by 3.4%, and the net loss increased by 2.6% in H1 2014.

Cash Position
MDxHealth ended the first half of 2014 with cash and cash equivalents of $12.7 million compared to $32.3 million on June 30, 2013. 

Q3 and FY2014 Outlook

In Q3 2014, MDxHealth will begin enrollment in its 600 patient, prospective clinical utility study, PASCUAL, which will generate additional clinical utility data supporting Medicare coverage of the ConfirmMDx for Prostate Cancer test.  MDxHealth anticipates that the final LCD for Medicare coverage of ConfirmMDx with data development will be effective in Q4 2014.  An interim analysis of the PASCUAL study, as outlined in the Medicare LCD, is expected in the first half of 2015, potentially triggering expanded coverage.

A steady increase in reimbursement from third-party payors was achieved during the period, with more than 155 insurers now paying for the test. With increasing ConfirmMDx test volumes and collections, MDxHealth is able to recognize more accrual-based revenue.  However, with growing adoption of the test by new prescribing urologists across the U.S., the company expects a growing number of new payors, thus also increasing the group of non-contracted, third party payors.  This could lead to continued delays in collections and revenue recognition among those payors. Any projections provided herein should be considered forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.

MDxHealth licensee Exact Sciences recently reported on the successful completion of their FDA preapproval inspection (PAI).  CMS initiated National Coverage Analysis for screening for colorectal cancer using Cologuard, and posted the related Proposed Decision Memorandum on the CMS website. Exact Sciences reported that it is preparing for commercialization of its Cologuard test, most recently completing the training of an eighty-person direct sales force. In August, Cologuard received FDA approval and the product launch is expected before the end of 2014.  MDxHealth is entitled to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.

About MDxHealth

MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company's tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at twitter.com/mdxhealth .

Statutory Auditor's Limited Review Report

We have reviewed the accompanying interim consolidated statement of financial position of MDxHealth SA as of 30 June 2014 and the related interim consolidated statements of comprehensive income, cash flows and changes in equity for the six-month period then ended, as well as the explanatory notes. The Board of Directors is responsible for the preparation and presentation of this consolidated interim financial information in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union.

Zaventem, August 21, 2014

BDO Bedrijfsrevisoren Burg. Ven. CBVA / BDO Réviseurs d'Entreprises Soc. Civ. SCRL - Statutory auditor - Represented by Bert Kegels

Complete Financial Statements:
To download the 2014 interim report, go to: http://www.mdxhealth.com/investors/financials

For more information:

Dr Jan Groen, CEO Mike Sinclair (media)
MDxHealth Halsin Partners
US : +1 949 812 6979 UK: +44 20 7318 2955 
BE: +32 4 364 20 70 Cell: +44 7968 022075
info@mdxhealth.com msinclair@halsin.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

To access the PDF version, click here http://hugin.info/137314/R/1850111/645912.pdf

HUG#1850111

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 0

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 37

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 87

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Piper Sandler Welcomes John Kerins to Healthcare Team

Updated Category News Views 218

Piper Sandler Expands Healthcare Investment Banking Expertise Piper Sandler Companies (NYSE: PIPR), a prominent name in investment banking, is excited to announce a significant addition to their healthcare investment banking team with the hiring of John Kerins as a managing director. This strategic move reflects the firm’s commitment to strengthening its presence in the...

Continue Reading
Exploring North America's Last Mile Delivery Growth and Trends

Updated Category News Views 346

Exploring North America's Last Mile Delivery Growth and Trends The last mile delivery market in North America is poised for significant growth over the next few years. Experts estimate that this market could expand by USD 14.9 billion between 2025 and 2029. This impressive growth is being driven primarily by the increasing demand for business-to-consumer (B2C) e-commerce....

Continue Reading
Mastercard Marks 20 Years on NYSE with Digital Shift

Updated Category News Views 39

A Landmark Moment at the NYSE for Mastercard Ah, another day in the whirlwind of the stock universe, where birthdays are celebrated with the finesse of boardroom discussions. Mastercard (NYSE: MA) is taking a well-deserved spotlight as it cheers two decades since it hit the seal of the New York Stock Exchange. Back on May 26th, it wasn't just business as usual. Nope, they...

Continue Reading
Insights into the Expanding Network of China-Europe Freight Trains

Updated Category News Views 236

The Rise of China-Europe Freight Trains Recently, a significant milestone was reached when the 110,000th China-Europe freight train departed from Jiaozhou Station, fully loaded with various goods such as electronic displays and household appliances. This service has now transported goods worth over USD 450 billion, showcasing its crucial role in global trade. The Journey...

Continue Reading
Netflix Investors Encouraged to Report Losses Amid Investigation

Updated Category News Views 217

Investigation Focus on Netflix, Inc. (NASDAQ: NFLX) Recently, significant scrutiny has emerged surrounding Netflix, Inc. (NASDAQ: NFLX), as Edelson Lechtzin LLP, a prominent national law firm known for handling class action lawsuits, initiates an investigation into potential violations of federal securities laws. This inquiry seeks to determine whether Netflix and certain...

Continue Reading